IL161915A0 - Salt forms of methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)- quinazolin-6-yl)-allyl)-acetamide, its prepar - Google Patents

Salt forms of methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)- quinazolin-6-yl)-allyl)-acetamide, its prepar

Info

Publication number
IL161915A0
IL161915A0 IL16191502A IL16191502A IL161915A0 IL 161915 A0 IL161915 A0 IL 161915A0 IL 16191502 A IL16191502 A IL 16191502A IL 16191502 A IL16191502 A IL 16191502A IL 161915 A0 IL161915 A0 IL 161915A0
Authority
IL
Israel
Prior art keywords
yloxyl
prepar
quinazolin
phenylamino
pyridin
Prior art date
Application number
IL16191502A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL161915A0 publication Critical patent/IL161915A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16191502A 2001-12-12 2002-11-11 Salt forms of methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)- quinazolin-6-yl)-allyl)-acetamide, its prepar IL161915A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34088501P 2001-12-12 2001-12-12
PCT/IB2002/004708 WO2003050108A1 (en) 2001-12-12 2002-11-11 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer

Publications (1)

Publication Number Publication Date
IL161915A0 true IL161915A0 (en) 2005-11-20

Family

ID=23335337

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16191502A IL161915A0 (en) 2001-12-12 2002-11-11 Salt forms of methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)- quinazolin-6-yl)-allyl)-acetamide, its prepar

Country Status (34)

Country Link
US (1) US6844349B2 (uk)
EP (1) EP1456199A1 (uk)
JP (1) JP4202926B2 (uk)
KR (1) KR20040065259A (uk)
CN (1) CN1608062A (uk)
AP (1) AP2004003059A0 (uk)
AR (1) AR037772A1 (uk)
AU (1) AU2002366581A1 (uk)
BR (1) BR0214876A (uk)
CA (1) CA2469889A1 (uk)
DO (1) DOP2002000544A (uk)
EA (1) EA007412B1 (uk)
EC (1) ECSP045148A (uk)
GE (1) GEP20063872B (uk)
GT (1) GT200200272A (uk)
HR (1) HRP20040530A2 (uk)
HU (1) HUP0402662A2 (uk)
IL (1) IL161915A0 (uk)
IS (1) IS7227A (uk)
MA (1) MA27095A1 (uk)
MX (1) MXPA04005678A (uk)
NO (1) NO20042925L (uk)
NZ (1) NZ532436A (uk)
OA (1) OA12735A (uk)
PA (1) PA8561401A1 (uk)
PE (1) PE20030716A1 (uk)
PL (1) PL370858A1 (uk)
RS (1) RS46404A (uk)
TN (1) TNSN04112A1 (uk)
TW (1) TW200301103A (uk)
UA (1) UA75482C2 (uk)
UY (1) UY27572A1 (uk)
WO (1) WO2003050108A1 (uk)
ZA (1) ZA200402995B (uk)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002339687A1 (en) * 2001-12-12 2003-06-23 Pfizer Products Inc. Quinazoline derivatives for the treatement of abnormal cell growth
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
WO2004054585A1 (en) * 2002-12-18 2004-07-01 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
BR0317259A (pt) * 2002-12-19 2005-11-08 Pfizer Prod Inc Complexos de e-2-metóxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-ilóxi)-fenil amino]- quinazolin-6-il}-alil)-acetamida, seus métodos de produção e utilização
ATE490788T1 (de) 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
CN1838959A (zh) * 2003-08-18 2006-09-27 辉瑞产品公司 Erbb2抗癌剂的给药方案
CA2537812C (en) 2003-09-26 2013-01-22 Exelixis, Inc. C-met modulators and method of use
BRPI0415836A (pt) * 2003-10-27 2007-01-02 Merck & Co Inc composto, métodos para a modulação da atividade de receptor de quimocina em um mamìfero, e para o tratamento, a melhoria, o controle ou a redução do risco de uma doença ou distúrbio inflamatório e imunorregulatório, e de artrite reumatóide, composição farmacêutica
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
WO2005121124A1 (en) * 2004-06-07 2005-12-22 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4-[3-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and methods of preparing same
ES2720618T3 (es) 2004-07-27 2019-07-23 Gilead Sciences Inc Análogos de fosfonato de compuestos de inhibidores de VIH
US20080194596A1 (en) * 2005-06-03 2008-08-14 Frizer Inc. Therapeutic Combination Including a Selective Erbb2 Inhibitor
JP2008542356A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 異常な細胞増殖の治療用の二環式誘導体
CN101442994B (zh) * 2006-05-16 2013-03-06 吉里德科学公司 用于治疗恶性血液病的方法和组合物
JPWO2008072634A1 (ja) 2006-12-12 2010-04-02 武田薬品工業株式会社 縮合複素環化合物
ES2360014T3 (es) * 2006-12-21 2011-05-31 Pfizer Products Inc. Sal succinato de 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol-3-il)-fenoxi)metil)quinolina.
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
WO2009113560A1 (ja) 2008-03-12 2009-09-17 武田薬品工業株式会社 縮合複素環化合物
UA103329C2 (uk) 2008-07-08 2013-10-10 Гилиад Сайенсиз, Инк. Солі сполук-інгібіторів віл
CA2995880C (en) 2009-01-16 2021-01-05 Exelixis, Inc. Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
WO2017003668A1 (en) 2015-07-01 2017-01-05 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
CA3099440A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884418B1 (en) 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
AR007857A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
MXPA02012870A (es) * 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.

Also Published As

Publication number Publication date
AP2004003059A0 (en) 2004-06-30
JP2005511744A (ja) 2005-04-28
CN1608062A (zh) 2005-04-20
AU2002366581A1 (en) 2003-06-23
WO2003050108A1 (en) 2003-06-19
NO20042925L (no) 2004-09-07
TNSN04112A1 (fr) 2006-06-01
US6844349B2 (en) 2005-01-18
NZ532436A (en) 2006-01-27
MA27095A1 (fr) 2004-12-20
EA200400674A1 (ru) 2004-10-28
PL370858A1 (en) 2005-05-30
CA2469889A1 (en) 2003-06-19
JP4202926B2 (ja) 2008-12-24
UY27572A1 (es) 2003-07-31
US20030158217A1 (en) 2003-08-21
TW200301103A (en) 2003-07-01
UA75482C2 (en) 2006-04-17
PA8561401A1 (es) 2005-02-04
OA12735A (en) 2006-06-29
EA007412B1 (ru) 2006-10-27
KR20040065259A (ko) 2004-07-21
MXPA04005678A (es) 2004-12-06
WO2003050108A8 (en) 2003-12-18
ECSP045148A (es) 2004-07-23
DOP2002000544A (es) 2003-06-16
AR037772A1 (es) 2004-12-01
HRP20040530A2 (en) 2004-10-31
EP1456199A1 (en) 2004-09-15
PE20030716A1 (es) 2003-08-29
RS46404A (en) 2006-10-27
HUP0402662A2 (hu) 2005-05-30
GEP20063872B (en) 2006-07-10
GT200200272A (es) 2003-12-12
IS7227A (is) 2004-04-19
BR0214876A (pt) 2004-12-28
ZA200402995B (en) 2005-04-20

Similar Documents

Publication Publication Date Title
IL161915A0 (en) Salt forms of methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)- quinazolin-6-yl)-allyl)-acetamide, its prepar
DE60233833D1 (de) Hautfreundliches hakenförmiges Befestigungselement
DK1451192T3 (da) Ny krystallinsk forbindelse
HK1070071A1 (en) New pyrimidine compounds
AU2002312370A1 (en) Antipathogenic benzamide compounds
IL157109A0 (en) Quinazolines as mmp-13 inhibitors
HK1081527A1 (en) Processes for the preparation of 4-[4-[4-(2-cyanoethenyl)-2,6- dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AU2003213092A8 (en) Syntheses of quinazolinones
HUP0401248A3 (en) Preparation of aminopyrimidine compounds and new intermediates
DE60201799D1 (de) Lösbares Befestigungsclip
IS7287A (is) Pýrimídín efnasambönd
EP1558260A4 (en) CHINAZOLINONE COMPOUNDS AS CALCILYTIC
NO20035573L (no) Kinazolinderivater
IL213960A0 (en) 2-(substituted phenyl)-2-hydroxyl -ethyl carbamates
NO20035713L (no) Forbindelsesforankring
AU2002359574A8 (en) Antisense modulation of g protein-coupled receptor etbr-lp-2 expression
NO20042613L (no) Ny anvendelse for behandling av gastroosofagial refluks
DE50211819D1 (de) Polyacryl-Haftklebemassen
GB0112322D0 (en) Synthesis of chiral intermediates
EP1444231A4 (en) AMINO SALTS OF AN INTEGRIN RECEPTOR ANTAGONIST
FI20012552A (fi) Metallikarbonaatin valmistusmenetelmä
TW592370U (en) Angle adjustment structure of drum set
TW535936U (en) Stabilizing sheet of heat sink
DK200100218U3 (da) Overfladebelægning af sten
AU2002251664A1 (en) Use of npy y2 receptor antagonists